

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcements of PuraPharm Corporation Limited (the “**Company**”) dated 25 July 2025 (the “**Announcement**”) in relation to, among others, the Patent Licence Agreement and the Subscription Agreement. Unless the context requires otherwise, capitalized terms used herein shall bear the same meanings as defined in the Announcement.

As disclosed in the announcement dated 25 July 2025, the circular (the “**Circular**”) containing, among other things, (i) further details of the Patent Licence Agreement and the transactions contemplated thereunder; (ii) a letter from the Independent Board Committee in relation to the Patent Licence Agreement; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in relation to the Patent Licence Agreement and the transactions contemplated thereunder; (iv) the Valuation Report; (v) the Subscription Agreement and the transactions contemplated thereunder; and (vi) a notice of the EGM, was expected to be despatched to the Shareholders no later than 15 August 2025.

As additional time is required to prepare and finalise certain information contained in the Circular and to arrange publication of the Circular, the date for despatch of the Circular is expected to be postponed to a date on or before 17 October 2025.

By order of the Board of
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 15 August 2025

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors are Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.